Targeted drugs and immunotherapy have been greatly applied in anti-tumor therapy (14, 15): if there is a BRAF V600E mutation, BRAF V600 mutant kinase inhibitors can be used to inhibit the BRAF V600 mutant kinase, block the BRAF/MEK/ERK signaling pathway, and inhibit tumor cell proliferation and survival. This evidence concerns the gene BRAF and neoplasm.